About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Company Statements 2022
Biocon Biologics
/
News – Posts
/
Company Statements
/
Company Statements 2022
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
Fri, 28-Apr-2023
Posted by: Biocon Biologics
No Comments
Biocon Biologics Consolidated Statement on USFDA Inspections
Wed, 31-Aug-2022
Posted by: Biocon Biologics
No Comments
Biocon Statement on Parts of the Charge Sheet Leaked to a Media Outlet
Thu, 25-Aug-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru
Tue, 05-Jul-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics issues a statement in response to the media reports related to bribery allegations
Tue, 21-Jun-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Denies Bribery Allegations
Tue, 21-Jun-2022
Posted by: Biocon Biologics
No Comments
The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart
Fri, 07-Jan-2022
Posted by: Biocon Biologics
No Comments
